Emerging therapeutic options for CMD include nonsteroidal anti-inflammatory drugs such as colchicine and interleukin-1 (IL-1) blockers, which may prevent endothelial inflammation and reduce the risk of HF and stroke. The gene discussed is IL1B; the disease is stroke disorder.